Back to News
Market Impact: 0.28
Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
Source: Business Wire
Healthcare & BiotechPatents & Intellectual PropertyProduct Launches
Elvinix secured an exclusive license to Zealand Pharma's GLP-1/gastrin dual-agonist peptides for development of a regenerative therapy targeting type 1 diabetes. The licensing agreement expands Elvinix's therapeutic-development capabilities in a high-need diabetes indication, though no financial terms, clinical data, or development timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ZEAL0.50
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns